Loading
Life sciences · Journal article
Exploration of Targeted Anti-tumor Therapy · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aim: Treatment approaches for biliary tract cancer (BTC) vary widely. Genomic profiling through next-generation sequencing (NGS) has made it possible to apply precision medicine in the management of BTC. This retrospective observational study aimed to evaluate the implementation of treatments based on identified genomic mutations and their clinical significance in patients with BTC in Japan, where NGS is covered by health insurance. Methods: We conducted a retrospective analysis of 65 patients with unresectable or recurrent BTC who underwent comprehensive genomic profiling at a single institution between November 2019 and October 2024. Genomic mutations were classified according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scale. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Results: Among the 65 patients, clinically relevant genomic mutations classified using the ESCAT scale were identified in 47 patients, and clinically treatable genomic mutations were identified in 13 patients. Six patients ultimately received mutation-guided therapy, including fibroblast growth factor receptor inhibitors and pembrolizumab. The median time from specimen submission to review by the expert panel was 26 (range, 16–40) days. No significant difference in OS was observed based on the site of the primary tumor (log-rank test, P = 0.5804). Conclusions: Although clinically actionable genomic mutations were identified in one-fifth of patients, < 10% ultimately received treatment based on those findings, highlighting a gap between genomic profiling and treatment implementation. In contrast, with the increasing number of available therapies, access to precision treatment for patients with BTC may improve in the future through a combination of early adoption of NGS and the complementary use of liquid biopsy when tissue is unavailable.